Related Experiment Videos
Interleukin-1 in disease
1Department of Medicine, Tufts University School of Medicine, New England Medical Center Hospital, Boston, MA.
The Keio Journal of Medicine
|September 1, 1994
Summary
Blocking the inflammatory cytokine interleukin-1 (IL-1) offers a unique therapeutic advantage by targeting disease-specific pathways. This approach spares essential physiological functions, unlike broader anti-inflammatory drugs.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- The inflammatory cytokine interleukin-1 (IL-1) plays a key role in various pathological processes.
- Blocking IL-1 activity is a therapeutic strategy for numerous diseases.
Purpose of the Study:
- To review the diverse modalities used to inhibit IL-1 production and/or activity.
- To highlight the pharmacological advantages of targeting IL-1 in disease.
Main Methods:
- Review of various agents targeting IL-1 at different levels: transcription, synthesis, processing, secretion, receptor binding, and signal transduction.
- Discussion of clinical trial progress for IL-1 blocking agents.
- Comparison of IL-1 blockade with traditional anti-inflammatory drugs like cyclooxygenase inhibitors.
Main Results:
- Multiple strategies exist to inhibit IL-1, with some already in clinical trials.
- Targeting IL-1 offers a unique advantage by reducing pathological effects without compromising host defense and homeostasis.
- IL-1 blockade spares the synthesis of physiologically essential prostaglandins and nitric oxide.
Conclusions:
- Blocking IL-1 provides a targeted therapeutic approach for inflammatory diseases.
- This strategy offers a significant pharmacological advantage over non-specific anti-inflammatory agents.
- Further development of IL-1 blocking agents holds promise for treating a range of diseases.